Clinical outcome of pharmacist-led prospective audit with intervention and feedback after expansion from patients using specific antibiotics to those using whole injectable antibiotics.
Administration, Intravenous
Anti-Infective Agents
/ administration & dosage
Antimicrobial Stewardship
Controlled Before-After Studies
Drug Resistance, Bacterial
Drug Utilization
/ statistics & numerical data
Humans
Japan
Length of Stay
/ statistics & numerical data
Medical Overuse
/ prevention & control
Pharmacists
Program Evaluation
Antimicrobial resistance
Antimicrobial stewardship
Intervention
Japan
Pharmacist
Prospective audit with intervention and feedback
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
05
11
2018
accepted:
26
12
2018
pubmed:
27
1
2019
medline:
13
9
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
Prospective audit with intervention and feedback (PAF) and preauthorisation of antimicrobials are core strategies for antimicrobial stewardship (AS). PAF participants were expanded from patients using specific antibiotics to those using whole injectable antibiotics to evaluate clinical outcome. From January 2016 to December 2016, PAF was performed in patients using specific antibiotics (period 1) and from January 2017 to December 2017, PAF was performed in patients using whole injectable antibiotics (period 2). PAF was implemented for 5 days every week by pharmacists involved in infectious diseases chemotherapy. In total, 11,571 and 11,103 patients used antibiotic injections during periods 1 and 2, respectively. No significant difference in mortality within 30 days from the initial use of injection antibiotics was observed. The average duration of hospitalisation was significantly shorter during period 2 among patients using antibiotics; however, this was not significantly different from that of patients not receiving antibiotics. The average duration of therapy for intravenous antibiotics was significantly shorter during period 2 than during period 1. The ratio of methicillin-resistant Staphylococcus aureus (MRSA) to S. aureus was significantly low during period 2. The duration of intravenous antibiotic therapy for Escherichia coli bacteraemia during period 2 decreased significantly. De-escalation and appropriate antimicrobial treatment rates at specific doses during period 2 increased significantly. Expansion of patients eligible for PAF from patients using specific antibiotics to patients using whole injectable antibiotics shortened hospital stays, suppressed drug resistance, and promoted the appropriate use of antibiotics.
Identifiants
pubmed: 30680565
doi: 10.1007/s10096-018-03465-z
pii: 10.1007/s10096-018-03465-z
doi:
Substances chimiques
Anti-Infective Agents
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
593-600Références
Int J Antimicrob Agents. 1999 Jan;11(1):7-12
pubmed: 10075272
Ann Intern Med. 2002 Nov 19;137(10):791-7
pubmed: 12435215
Nephron. 1976;16(1):31-41
pubmed: 1244564
Antimicrob Agents Chemother. 2008 Mar;52(3):813-21
pubmed: 18070961
Infect Control Hosp Epidemiol. 2011 Apr;32(4):367-74
pubmed: 21460488
Int J Clin Pharm. 2011 Apr;33(2):208-14
pubmed: 21744190
Int J Clin Pharm. 2011 Dec;33(6):929-33
pubmed: 22068326
Int J Clin Pract. 2012 Oct;66(10):999-1008
pubmed: 22846073
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Pharm Policy Pract. 2014 Aug 05;7(1):10
pubmed: 25136450
J Antimicrob Chemother. 2015 Apr;70(4):1245-55
pubmed: 25527272
Lancet Infect Dis. 2015 Dec;15(12):1438-49
pubmed: 26411518
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
Med Mal Infect. 2017 Mar;47(2):92-141
pubmed: 28279491
Yakugaku Zasshi. 2017;137(5):643-650
pubmed: 28458296
Infection. 2017 Oct;45(5):613-620
pubmed: 28478600
Int J Infect Dis. 2017 Nov;64:69-73
pubmed: 28941633
Infection. 2018 Apr;46(2):215-224
pubmed: 29134582
J Antimicrob Chemother. 2018 Apr 1;73(4):1084-1090
pubmed: 29346568
Clin Microbiol Infect. 2018 Nov;24(11):1184-1189
pubmed: 29408612
Int J Clin Pract. 2018 Mar;72(3):e13065
pubmed: 29418054
Pharmazie. 2017 May 1;72(5):296-299
pubmed: 29441876
Antimicrob Resist Infect Control. 2018 May 2;7:63
pubmed: 29744044
J Gen Fam Med. 2018 Feb 20;19(3):82-89
pubmed: 29744261
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716